HeadInvest LLC’s Regeneron Pharmaceuticals REGN Stock Holding History

HeadInvest LLC’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25	Closed	-$20.5K	–	583
2023 Q3	$20.5K	Buy	+25	New	+$19.6K	﹤0.01%	462

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HeadInvest LLC's REGN Position: Q4 2023 in Review

HeadInvest LLC sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 25 shares — an estimated $20.5K sold.

HeadInvest LLC first reported a position in REGN in Q3 2023 and held it in 1 quarter. The position peaked at $20.5K in Q3 2023. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

HeadInvest LLC reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
HeadInvest LLC sold 25 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $20.5K.
HeadInvest LLC first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 1 quarter.
HeadInvest LLC's Regeneron Pharmaceuticals position peaked at $20.5K in Q3 2023.
1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on HeadInvest LLC's 13F filing for Q4 2023, filed 12 Feb 2024.